Immunotherapy post-surgery improves overall survival for kidney cancer
Boston – For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer. Credit: Dana-Farber Cancer Institute Boston – For the first time in fifty years,